Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
The top three most advertised brands in 2016 were Gilead Sciences’ Harvoni, Eli Lilly’s Trulicity, and J&J’s Invokana.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Valeant added 250 primary care sales reps to promote its Salix portfolio.
Acorda CEO Ron Cohen applauded Marathon’s move to pause the commercial activities for its new DMD drug.
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
Thirty-percent of Keytruda’s U.S. sales came from its lung-cancer indication.
Merck details price increases for its drugs; Trump’s call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
MM+M Transform: The Patient, Provider and Payer Engagement Matrix provides the most in-depth look at the marketing and technology trends likely to influence the industry’s growth over the next year.
Get the most out of
Register for free and enjoy unlimited access to: